Trial Profile
A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2020
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms PNEUMON
- Sponsors Roche
- 20 Aug 2020 Status changed from active, no longer recruiting to completed.
- 14 Apr 2020 Planned End Date changed from 31 Jan 2020 to 30 May 2020.
- 14 Apr 2020 Planned primary completion date changed from 31 Jan 2020 to 30 May 2020.